Biotechnology Startups

Solugen develops a biomanufacturing platform using fermentation and bioprocessing technology to produce specialty chemicals at scale. The company serves customers in energy, chemicals, and related industries with cost-effective alternatives to traditional petrochemical-based manufacturing.

21 investors

Mytos develops automated manufacturing technology for regenerative medicines, specifically targeting the production of stem cell-derived therapies to make treatments for conditions like Parkinson's, blindness, and spinal cord injury accessible and affordable to patients.

10 investors

Sensible Biotechnologies develops a cell-based mRNA design and manufacturing platform that produces pure, low immunogenicity mRNA therapeutics for drug development. The platform addresses limitations of synthetic mRNA by enabling design-based biology approaches.

5 investors

SFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.

5 investors

Lygos uses genetically engineered microorganisms to produce industrial chemicals from sugar feedstocks, focusing on compounds where fermentation offers cost advantages compared to fossil fuel-based manufacturing.

4 investors

Volta develops a hardware and software platform for genomics sample preparation that automates the extraction of biological information. The company serves researchers, laboratories, and healthcare organizations working in genomics, disease control, forensic science, and medicine.

3 investors

Alixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.

2 investors

Scoop converts scientific and manufacturing data into dynamic regulatory documents for drug submissions, using AI to continuously reconcile updates and maintain consistency across filings for pharmaceutical companies and regulatory teams.

2 investors

Uncommon Therapeutics uses advanced technologies to develop drugs targeting rare genetic diseases, starting with Rett Syndrome, a neurodevelopmental disorder affecting approximately 1 in 10,000 girls. The company combines disease expertise with efficient drug development to advance therapeutics from discovery to clinical application.

2 investors

UrbanKisaan develops machine learning models and hardware systems for accelerated plant breeding. The company creates foundation models that predict plant traits from genetic sequences and environmental data, paired with controlled-environment chambers that compress traditional multi-year breeding cycles into months by enabling rapid generations and continuous phenotype data collection.

2 investors

AtlasDiscovery develops foundation models of patient drug response trained on pre-clinical and clinical data to improve drug trial design and success rates. The company serves pharmaceutical and biotech firms by predicting human drug responses and enabling drug rescue and development in the biotech industry.

1 investor

Tissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.

1 investor

Evolvere BioSciences develops antibiotics using computational models and evolutionary data to target pathogenic bacteria while preserving beneficial microbes, designed to resist the development of bacterial resistance.

1 investor

Nexa develops implantable microchips and herd management software for farmers to monitor cattle health and detect disease early. The platform combines subcutaneous sensors with a mobile/web interface to provide real-time health insights and breeding optimization for dairy and cattle operations.

1 investor

Ritivel builds an AI-native platform that automates regulatory workflows and documentation for life sciences companies, helping accelerate the submission of therapies to patients.

1 investor

TareBio operates a platform for developing personalized and population-level vaccines against cancer and infectious diseases by analyzing immune cells already responding to a disease and reverse-engineering the antigens that activate them. The company works in the biotechnology and vaccine development space.

1 investor

Taxa collaborates with government administrations and businesses to deliver technology solutions that improve community engagement and administrative operations.

1 investor